Clinical Pearls and Future Perspectives in Advanced NSCLC

EP: 1.First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

EP: 2.The Role of CTLA-4 Inhibitors in NSCLC

EP: 3.NSCLC: PD-L1 Expression and Treatment Decision-Making

EP: 4.TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

EP: 5.Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

EP: 6.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

EP: 7.TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

EP: 8.A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

EP: 9.First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

EP: 10.FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

EP: 11.MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

EP: 12.Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 13.MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 14.Antibody-Drug Conjugates in EGFR-Mutant NSCLC

Now Viewing

EP: 15.Clinical Pearls and Future Perspectives in Advanced NSCLC

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

In concluding thoughts, speakers Dr Joshua K. Sabari, assistant professor of medicine at NYU Langone Health, Dr Marina Garassino, and Dr Solange Peters emphasized the need for comprehensive molecular profiling to match all patients with non–small cell lung cancer (NSCLC) to optimal targeted therapies or immunotherapies. They consider the phase 3 MARIPOSA trial combining chemotherapy, the anti-EGFR antibody amivantamab, and the EGFR tyrosine kinase inhibitor (TKI) lazertinib very promising for frontline EGFR-mutant NSCLC but await full overall survival data. Dr Garassino highlighted the importance of patient involvement in selecting among emerging regimens balancing efficacy and toxicity.

Dr Peters noted antibody-drug conjugate (ADC) therapies may soon play a greater role, especially after progression on prior targeted and immune therapies, giving community oncologists challenging sequencing decisions requiring expert input. Dr Edward Garon advocated accrual to clinical trials driving recent advances. All speakers stressed the value of a diverse, multidisciplinary team in caring for this complex patient population. Discussants agreed it is an exciting time in lung cancer, with rapid therapeutic evolution requiring new strategies to optimize outcomes. Ongoing studies of novel combinations and ADCs in biomarker-defined subgroups will clarify treatment paradigms. But open communication, referral networks, and trial participation are vital to promote equitable access to the latest scientific breakthroughs for all patients with NSCLC in community and academic settings alike.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.